ALNY Stock Price Today (October 2026) — Alnylam Pharmaceuticals, Inc. Analysis & Key Metrics 2026-10-20
Alnylam Pharmaceuticals, Inc. (ALNY) is trading at $230.71, down 1.11% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $368.71 (59.8% upside).
- Volatility is moderate (38.23% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (66.90% YoY) alongside competitive pressures in the Biotechnology space.
ALNY Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Alnylam Pharmaceuticals, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $30.55B
P/E Ratio
Forward P/E: 19.12
Revenue Growth
Year over Year
Analyst Target
+59.8% upside potential
Key Investor Questions About ALNY
What investors need to know before buying
Based on current market data, ALNY presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 46.37)
- Fundamentals say: Mixed signals (nuanced financial profile)
ALNY's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ALNY investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $2.99B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ALNY stock traded between $197.81 and $495.55 and currently trades near the low end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 38.23% annualized volatility and β=0.48, the stock exhibits low sensitivity to market moves—making ALNY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?
What First Trust NYSE Arca Biotech (FBT) Bought: Tarsus Leads on Oct. 16
Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%
What Is The Case For Waiting On Moderna Stock?
Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings
Latest TickZen Insights
All insights →No TickZen article on ALNY yet. Our newest analysis:
Explore More Analysis for ALNY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) is currently trading at $230.71. The RSI (14-day) is at 46.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $368.71 implies 59.8% upside from current levels. Volatility is moderate at 38.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Alnylam Pharmaceuticals, Inc. (ALNY): The trailing P/E ratio is 42.95, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 19.12, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.45, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 24.69. Price-to-Sales is 6.96. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 27 analysts covering ALNY, the consensus price target is $368.71. This represents a 59.8% upside from the current price of $230.71. The range spans from a low target of $250.00 to a high target of $536.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Alnylam Pharmaceuticals, Inc. (ALNY) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Alnylam Pharmaceuticals, Inc. (ALNY) investors include: 1. Moderate volatility (38.2% annualized)—price swings are notable. 2. Elevated debt levels (debt-to-equity of 2.21x) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Alnylam Pharmaceuticals, Inc.'s (ALNY) current debt and financial health profile: Total debt stands at $2.99B. The debt-to-equity ratio is 2.21x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 3.06, indicating strong short-term liquidity. The quick ratio is 2.79. The company holds $3.31B in cash and equivalents. Free cash flow is positive at $271.54M, providing a cushion for debt servicing and shareholder returns.